AP
APRE.US Aprea Therapeutics Inc
- Market cap
- USD 6.13M
- P/E
- -
- P/B
- 0.18x
- ROE
- -45.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is APRE.US undervalued?
Graham numberThe Graham number of Aprea Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aprea Therapeutics Inc fundamental analysis
No fundamental analysis for Aprea Therapeutics Inc yet.
Aprea Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clini…
Full company profileAprea Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aprea Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 583K | 1.50M | 286K | 0.00 |
| Gross Profit | 0.00 | -7.93K | -8.32K | -170K | -230K | -272K | -16.4M | 576K | -7.86M | 264K | - |
| Operating Income | -246K | -15.9M | -16.5M | -29.5M | -52.8M | -37.4M | -113M | -15.5M | -14.3M | -13.2M | -16.8M |
| EBITDA | - | -15.2M | -15.5M | -27.9M | -53.2M | -36.9M | -37.2M | -14.3M | -12.9M | -12.6M | -16.1M |
| Net Income | -436K | -15.2M | -15.5M | -28.1M | -53.9M | -36.5M | -113M | -14.3M | -13.0M | -12.6M | -15.6M |
| EPS | - | -22 | -22 | -28 | -51 | -34 | -1,360 | -3.95 | -2.35 | -1.93 | -0.29 |
| Balance Sheet | |||||||||||
| Total Assets | - | 24.8M | 66.0M | 134M | 92.8M | 56.8M | 30.2M | 22.7M | 24.0M | 15.9M | 38.8M |
| Total Liabilities | 5.70M | 60.5M | 117M | 9.36M | 15.4M | 7.32M | 4.51M | 4.39M | 4.67M | 3.49M | 4.70M |
| Shareholders' Equity | - | -35.8M | -51.4M | 124M | 77.4M | 49.5M | 25.6M | 18.3M | 19.3M | 12.4M | 34.1M |
| Cash & Short-term Investments | - | 24.4M | 65.7M | 130M | 89.0M | 53.1M | 28.8M | 21.6M | 22.8M | 14.6M | 37.8M |
| Total Debt | - | - | - | 545K | 335K | 190K | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -14.0M | -15.3M | -26.7M | -41.8M | -37.7M | -25.0M | -12.2M | -13.6M | -12.9M | -13.0M |
| Capital Expenditure | 0.00 | 3.70K | 3.70K | 30.9K | 25.7K | 0.00 | 0.00 | 93.1K | 15.5K | 0.00 | 20.5K |
| Free Cash Flow | - | -14.0M | -15.3M | -26.7M | -41.8M | -37.7M | -25.0M | -12.3M | -13.6M | -12.9M | -13.0M |
| Ratios | |||||||||||
| ROE | - | - | - | -22.6% | -69.7% | -73.8% | -439.3% | -78.2% | -67.1% | -101.3% | -45.7% |
| ROA | - | -61.3% | -23.5% | -21.0% | -58.1% | -64.3% | -373.6% | -63.1% | -54.0% | -79.1% | -40.2% |
| Net Profit Margin | - | - | - | - | - | - | - | -2,449.6% | -862.4% | -4,409.2% | - |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aprea Therapeutics Inc dividends
Aprea Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Feb 13, 2023.
Who owns Aprea Therapeutics Inc
- Insiders 9.17%
- Institutions 18.83%
- Public & others 71.99%
- Shares outstanding 14.2M
- Free float 7.90M
Top funds holding APRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 59.6K | 0.42% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 7.20K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 5.85K | 0.04% | 0.00% | Sep 2026 |
| BlackRock Diversified Equity Alpha Inst | 289.00 | 0.00% | 0.00% | Jul 2026 |
Top institutions holding APRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AIGH Capital Management, LLC | 1.02M | 8.07% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 412K | 3.27% | +100.00% | Jun 2026 |
| Vestal Point Capital LP | 350K | 2.78% | 0.00% | Jun 2026 |
| Sphera Funds Management Ltd. | 270K | 2.14% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 106K | 0.84% | +321.51% | Jun 2026 |
| Geode Capital Management, LLC | 74.9K | 0.59% | -37.15% | Jun 2026 |
| Citadel Advisors Llc | 58.6K | 0.47% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 45.2K | 0.36% | +13.55% | Jun 2026 |
| Diadema Partners LP | 44.9K | 0.36% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 38.5K | 0.31% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 34.9K | 0.28% | +168.39% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 25.8K | 0.21% | +15.67% | Jun 2026 |
| Vanguard Capital Management, LLC | 22.9K | 0.18% | +16.61% | Jun 2026 |
| LPL Financial Corp | 16.1K | 0.13% | -23.75% | Jun 2026 |
| HighTower Advisors, LLC | 13.9K | 0.11% | 0.00% | Jun 2026 |
| Northern Trust Corp | 13.7K | 0.11% | 0.00% | Jun 2026 |
| Persistent Asset Partners Limited | 11.5K | 0.09% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 10.6K | 0.08% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.17K | 0.06% | -15.65% | Jun 2026 |
| Tower Research Capital LLC | 3.59K | 0.03% | -29.98% | Jun 2026 |
Aprea Therapeutics Inc company profile
- Company name
- Aprea Therapeutics Inc
- Ticker
- APRE.US
- Exchange
- USA Stocks
- Listed since
- Oct 3, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
- Fiscal year end
- December
- Address
- 3805 Old Easton Road, Doylestown, PA, United States, 18902
- Phone
- 215 948 4119
- Website
- aprea.com
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics Inc management
8- Dr. Oren Gilad Ph.D.Co-Founder, CEO, President & Director · born 1968
- Mr. John P. Hamill CPASenior VP, CFO, Principal Accounting Officer & Secretary · born 1964
- Dr. Lars B. Abrahmsen Ph.D.Senior VP & Chief Scientific Officer · born 1957
- Mr. Brian WileySenior Vice President of Corporate Development & Strategy · born 1968
- Dr. Michel Afargan Ph.D.Head of Pharmacology Development
- Mr. Ze'ev Weiss B.Sc., C.P.A.Chief Business Advisor · born 1962
- Dr. Eugene P. Kennedy F.A.C.S., M.D.Chief Medical Advisor · born 1969
- Ms. Andrea EpsteinController